

# Driving adoption of new technologies in biopharmaceutical manufacturing

Gene Schaefer<sup>1</sup>, John Balchunas<sup>1</sup>, Timothy Charlebois<sup>1</sup>, John Erickson<sup>1</sup>, Roger Hart<sup>1</sup>, Sandeep B. Kedia<sup>1</sup>, and Kelvin Lee<sup>1</sup>

<sup>1</sup>National Institute for Innovation in Manufacturing Biopharmaceuticals

November 30, 2022

## Abstract

The challenge of introducing new technologies into established industries is not a problem unique to the biopharmaceutical industry. However, it may be critical to the long-term competitiveness of individual manufacturers and, more importantly, the ability to deliver therapies to patients. This is especially true for new treatment modalities including cell and gene therapies. We review several barriers to technology adoption which have been identified in various public forums including business, regulatory, technology, and people-driven concerns. We also summarize suitable enablers addressing one or more of these barriers along with some suggestions for developing additional synergies.

## Hosted file

Technology-Adoption Schaefer FINAL.docx available at <https://authorea.com/users/558156/articles/607492-driving-adoption-of-new-technologies-in-biopharmaceutical-manufacturing>